Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Harutaka Seshimo

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 7, 2026 · JOURNAL ARTICLE

Three Cases of Merkel Cell Carcinoma Treated With Lutetium‐177 Oxodotreotide

The Journal of Dermatology

Three uncontrolled case reports of a salvage therapy in treatment-refractory merkel cell carcinoma, showing feasibility and safety but limited efficacy; early evidence requiring prospective study.

PreliminaryMisaki Kase Kenjiro Namikawa Harutaka Seshimo

Reported

Sample size3

Patient ages73, 45, 77 years

Survival from first PRRT (patient…3.4 months

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support